Apellis Pharmaceuticals Inc (APLS NASDAQ) stock market data APIs
$21.5775
-0.65(-3%)
as of October 31, 2025
Try our APIs with
free plan!
Apellis Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Prev. Close
21.5775
Open
20.9247
High
21.6842
Low
19.1957
52 wk Range
16.1-35.72
Market Cap
2 716 M
P/E Ratio
59.6389
Shares Outstanding
127 M
Revenue
1 016 M
EPS
-0.33
Beta
0.679
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Apellis Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apellis Pharmaceuticals Inc data using free add-ons & libraries
Get Apellis Pharmaceuticals Inc Fundamental Data
Apellis Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 1 016 M
- EBITDA: 82 083 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apellis Pharmaceuticals Inc News
New
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
Apellis Pharmaceuticals APLS reported third-quarter 2025 earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. The company had incurred a loss of 46 cents in the year-a...
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings
Apellis Pharmaceuticals (APLS) remains unprofitable, but earnings are forecast to grow by 66.7% annually, with the company expected to reach profitability within the next three years. Revenue growth i...
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Total Revenue: $459 million, including a $275 million upfront payment from Sobi. Pyo Net Product Revenue: $151 million for the quarter. Total Net Product Rev...
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Apellis Pharmaceuticals, Inc. (APLS) reported $458.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 133%. EPS of $1.67 for the same period compares...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
